Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Increlex for Growth Failure in XSCID
NCT00490100Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2007
- Primary completion
- Dec 2012
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of mecasermin in Growth failure (FTT), sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2007; status: terminated.
02
Drugs
mecasermin
03
Conditions
Growth failure (FTT)
Beyond the preview
Go deeper on NCT00490100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00490100.